Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 17;101(16):e1581-e1593.
doi: 10.1212/WNL.0000000000207727. Epub 2023 Aug 21.

Retinal Optical Coherence Tomography Features Associated With Incident and Prevalent Parkinson Disease

Collaborators, Affiliations

Retinal Optical Coherence Tomography Features Associated With Incident and Prevalent Parkinson Disease

Siegfried Karl Wagner et al. Neurology. .

Abstract

Background and objectives: Cadaveric studies have shown disease-related neurodegeneration and other morphological abnormalities in the retina of individuals with Parkinson disease (PD); however, it remains unclear whether this can be reliably detected with in vivo imaging. We investigated inner retinal anatomy, measured using optical coherence tomography (OCT), in prevalent PD and subsequently assessed the association of these markers with the development of PD using a prospective research cohort.

Methods: This cross-sectional analysis used data from 2 studies. For the detection of retinal markers in prevalent PD, we used data from AlzEye, a retrospective cohort of 154,830 patients aged 40 years and older attending secondary care ophthalmic hospitals in London, United Kingdom, between 2008 and 2018. For the evaluation of retinal markers in incident PD, we used data from UK Biobank, a prospective population-based cohort where 67,311 volunteers aged 40-69 years were recruited between 2006 and 2010 and underwent retinal imaging. Macular retinal nerve fiber layer (mRNFL), ganglion cell-inner plexiform layer (GCIPL), and inner nuclear layer (INL) thicknesses were extracted from fovea-centered OCT. Linear mixed-effects models were fitted to examine the association between prevalent PD and retinal thicknesses. Hazard ratios for the association between time to PD diagnosis and retinal thicknesses were estimated using frailty models.

Results: Within the AlzEye cohort, there were 700 individuals with prevalent PD and 105,770 controls (mean age 65.5 ± 13.5 years, 51.7% female). Individuals with prevalent PD had thinner GCIPL (-2.12 μm, 95% CI -3.17 to -1.07, p = 8.2 × 10-5) and INL (-0.99 μm, 95% CI -1.52 to -0.47, p = 2.1 × 10-4). The UK Biobank included 50,405 participants (mean age 56.1 ± 8.2 years, 54.7% female), of whom 53 developed PD at a mean of 2,653 ± 851 days. Thinner GCIPL (hazard ratio [HR] 0.62 per SD increase, 95% CI 0.46-0.84, p = 0.002) and thinner INL (HR 0.70, 95% CI 0.51-0.96, p = 0.026) were also associated with incident PD.

Discussion: Individuals with PD have reduced thickness of the INL and GCIPL of the retina. Involvement of these layers several years before clinical presentation highlight a potential role for retinal imaging for at-risk stratification of PD.

PubMed Disclaimer

Conflict of interest statement

S.K. Wagner is funded by the Medical Research Council (MR/TR000953/1) and the Rank Prize. D. Romero-Bascones received funding from the Basque Health Department (2022333011). M. Cortina-Borja, D.J. Williamson, R.R. Struyven, Y. Zhou, and S. Patel report no disclosures. R.S. Weil is supported by a Wellcome Clinical Research Career Development Fellowship (205167/Z/16/Z). C.A. Antoniades receives funding from the NIHR, Biomedical Research Centre (BRC), UCB-OXford collaborative grant, and Merck. E.J. Topol and E. Korot report no disclosures. P.J. Foster receives salary support from NIHR through a grant to the Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of Ophthalmology. K. Balaskas reports no disclosures. U. Ayala receives funding from the Basque Health Department (2022333011). M. Barrenechea receives funding from the Basque Health Department (2022333011). I. Gabilondo receives funding from the Basque Health Department (2022333011). A.H.V. Schapira reports no disclosures. A.P. Khawaja is supported by a UK Research & Innovation Future Leaders Fellowship (MR/T040912/1), an Alcon Research Institute Young Investigator Award and a Lister Institute Fellowship. A.P. Khawaja receives salary support from NIHR through a grant to the Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of Ophthalmology. P.J. Patel, J.S. Rahi, and A.K. Denniston report no disclosures. A. Petzold receives salary support from NIHR through a grant to the Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of Ophthalmology. P.A. Keane is supported by a UK Research & Innovation Future Leaders Fellowship (MR/T019050/1). P.A. Keane receives salary support from NIHR through a grant to the Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of Ophthalmology. Additional support was from the NIHR Birmingham, Great Ormond Street, Moorfields, Oxford, and University College London Hospitals Biomedical Research Centres. Go to Neurology.org/N for full disclosures.

Figures

Figure 1
Figure 1. Flowchart Detailing Inclusion and Exclusion of Participants in Both AlzEye and UK Biobank
PD = Parkinson disease.
Figure 2
Figure 2. Distribution of Retinal Sublayer Thicknesses in AlzEye and UK Biobank
Raincloud plots consisting of a density, box-whisker, and scatter plots for AlzEye (A–C) and UK Biobank (D–F) for individual retinal sublayers. Scatter points represent the mean of both eyes (where available) per participant. To improve visibility, a random 2% of control participants are illustrated.
Figure 3
Figure 3. Summary of Findings for Prevalent and Incident Parkinson Disease
Values are shown per parafoveal region and for the average of all inner segments (small donut). The effect measure corresponds to a color scale with warm colors indicating lower numbers. GCIPL = macular ganglion cell–inner plexiform layer; II = inner inferior; IN = inner nasal; INL = inner nuclear layer; IS = inner superior; IT = inner temporal; mRNFL = macular retinal nerve fiber layer.
Figure 4
Figure 4. Illustration of Cell Type Distribution in the Retina
An example optical coherence tomography scan of the nasal macula adjacent to schematic detailing interactions with dopaminergic amacrine cells. Dopaminergic cells (1) have dense plexi positioned throughout the inner plexiform and inner nuclear layers. They are presynaptic to amacrine AII cells (2), and some dopaminergic processes project toward the photoreceptor layer where they interact with horizontal cells (3). They are postsynaptic to bipolar cells (4). Previous work has demonstrated aggregation of proteins, including α synuclein, within the inner nuclear layer (5), which could result in impairment of nearby ganglion cells. GCIPL = macular ganglion cell–inner plexiform layer; INL = inner nuclear layer; PRL = photoreceptor layer; RNFL = retinal nerve fiber layer; RPE = retinal pigment epithelium.

References

    1. Biondetti E, Santin MD, Valabrègue R, et al. . The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson's disease. Brain. 2021;144(10):3114-3125. doi:10.1093/brain/awab191 - DOI - PMC - PubMed
    1. Morrish PK, Sawle GV, Brooks DJ. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain. 1996;119(2):585-591. doi:10.1093/brain/119.2.585 - DOI - PubMed
    1. Sun J, Lai Z, Ma J, et al. . Quantitative evaluation of iron content in idiopathic rapid eye movement sleep behavior disorder. Mov Disord. 2020;35(3):478-485. doi:10.1002/mds.27929 - DOI - PubMed
    1. Iranzo A, Valldeoriola F, Lomeña F, et al. . Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol. 2011;10(9):797-805. doi:10.1016/s1474-4422(11)70152-1 - DOI - PubMed
    1. Lee JY, Martin-Bastida A, Murueta-Goyena A, et al. . Multimodal brain and retinal imaging of dopaminergic degeneration in Parkinson disease. Nat Rev Neurol. 2022;18(4):203-220. doi:10.1038/s41582-022-00618-9 - DOI - PubMed

Publication types